C
Christoph M. Janitzek
Researcher at University of Copenhagen
Publications - 19
Citations - 597
Christoph M. Janitzek is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 9, co-authored 15 publications receiving 430 citations. Previous affiliations of Christoph M. Janitzek include Statens Serum Institut & Copenhagen University Hospital.
Papers
More filters
Journal ArticleDOI
Bacterial superglue enables easy development of efficient virus-like particle based vaccines
Susan Thrane,Susan Thrane,Christoph M. Janitzek,Christoph M. Janitzek,Sungwa Matondo,Mafalda Resende,Mafalda Resende,Tobias Gustavsson,Tobias Gustavsson,Willem A. de Jongh,Stine N. Clemmensen,Stine N. Clemmensen,Stine N. Clemmensen,Will Roeffen,Marga van de Vegte‑Bolmer,Geert-Jan van Gemert,Robert W. Sauerwein,John T. Schiller,Morten Nielsen,Morten Nielsen,Thor G. Theander,Thor G. Theander,Ali Salanti,Ali Salanti,Adam F. Sander,Adam F. Sander +25 more
TL;DR: The spy-VLP system constitutes a versatile and rapid method to develop highly immunogenic VLP-based vaccines and could facilitate rapid and unbiased screening of vaccine candidate antigens.
Journal ArticleDOI
Virus-like particle display of HER2 induces potent anti-cancer responses
Arianna Palladini,Susan Thrane,Christoph M. Janitzek,Jessica Pihl,Stine B. Clemmensen,Stine B. Clemmensen,Willem A. de Jongh,Thomas Mandel Clausen,Giordano Nicoletti,Lorena Landuzzi,Manuel L. Penichet,Tania Balboni,Marianna L. Ianzano,Veronica Giusti,Thor G. Theander,Morten Nielsen,Ali Salanti,Pier Luigi Lollini,Patrizia Nanni,Adam F. Sander +19 more
TL;DR: Using a novel virus-like particle (VLP) based vaccine platform, it is shown that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses.
Journal ArticleDOI
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
Cyrielle Fougeroux,Louise Goksøyr,Manja Idorn,Vladislav Soroka,Sebenzile K. Myeni,Robert Dagil,Christoph M. Janitzek,Max Søgaard,Kara Lee Aves,Emma W. Horsted,Sayit Mahmut Erdoğan,Sayit Mahmut Erdoğan,Tobias Gustavsson,Jerzy Dorosz,Stine B. Clemmensen,Laurits Fredsgaard,Susan Thrane,Elena Ethel Vidal-Calvo,Paul Khalifé,Thomas M. Hulen,Swati Choudhary,Michael Theisen,Susheel K. Singh,Asier Garcia-Senosiain,Linda van Oosten,Gorben P. Pijlman,Bettina Hierzberger,Tanja Domeyer,Blanka W. Nalewajek,Anette Strøbæk,Magdalena Skrzypczak,Laura F. Andersson,Søren Buus,Anette Stryhn Buus,Jan Pravsgaard Christensen,Tim J. Dalebout,Kasper Iversen,Lene Holm Harritshøj,Benjamin Mordmüller,Henrik Ullum,Line S. Reinert,Willem A. de Jongh,Marjolein Kikkert,Søren R. Paludan,Thor G. Theander,Morten Nielsen,Ali Salanti,Adam F. Sander +47 more
TL;DR: In this paper, two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein were developed.
Journal ArticleDOI
Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Christoph M. Janitzek,Christoph M. Janitzek,Sungwa Matondo,Susan Thrane,Susan Thrane,Morten Nielsen,Morten Nielsen,Reginald A. Kavishe,Steve Mwakalinga,Thor G. Theander,Ali Salanti,Ali Salanti,Adam F. Sander,Adam F. Sander +13 more
TL;DR: This study demonstrates that the high-density display of CSP on SpyTag-VLPs, significantly increases the level and quality of the vaccine-induced humoral response, compared to a control vaccine consisting of soluble CSP plus AP205 VLPs.
Journal ArticleDOI
A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA
Susan Thrane,Susan Thrane,Christoph M. Janitzek,Christoph M. Janitzek,Mette Ø. Agerbæk,Mette Ø. Agerbæk,Sisse B. Ditlev,Sisse B. Ditlev,Mafalda Resende,Mafalda Resende,Morten Nielsen,Morten Nielsen,Thor G. Theander,Thor G. Theander,Ali Salanti,Ali Salanti,Adam F. Sander,Adam F. Sander +17 more
TL;DR: A VLP vaccine display platform is developed by identifying regions of the HPV16 L1 coat protein where a biotin acceptor site (AviTagTM) can be inserted without compromising VLP-assembly, and it is demonstrated that the described Avi-L1 V LP-platform may serve as a versatile system for facilitating optimalVLP-display of large and complex vaccine antigens.